Gossamer's PAH Candidate Meets Primary Endpoint, Stumbles on Secondary Measure

Topline results from a Phase II study showed Gossamer Bio’s seralutinib met its primary efficacy endpoint in pulmonary arterial hypertension, the company announced Tuesday.